NFE2L2 and multiple sclerosis: Transcriptomic analysis identified many additional canonical pathways and regulatory networks linked to inflammation and immune function and related diseases, particularly multiple sclerosis, for which a Nrf2 activator (dimethyl fumarate) is FDA-approved.